relapse – Medxy AI

Predicting Short-Term Outcomes in Pemphigus Patients Treated with Rituximab and Glucocorticoids: Insights from a Multicenter Chinese Cohort

By MedXY 10/02/2026

This multicenter retrospective study identifies key baseline predictors influencing short-term remission and relapse in pemphigus patients treated with rituximab plus glucocorticoids, guiding personalized treatment strategies.

Hematology-Oncology news Pediatrics

Tisagenlecleucel for Post-Transplant Relapse in Young Acute Lymphoblastic Leukemia Patients: European Real-World Determinants of Outcome

By MedXY 09/16/2026

This study evaluates the outcomes and critical factors influencing the success of tisagenlecleucel therapy for children and young adults with B-cell acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplant across Europe.

Hematology-Oncology news

Impact of Induction Course Number on Outcomes of Allogeneic Stem Cell Transplant with Post-Transplant Cyclophosphamide in AML

By MedXY 09/12/2026

This study compares outcomes after allogeneic stem cell transplantation using post-transplant cyclophosphamide in AML patients achieving first remission with one versus two induction courses, revealing similar survival but higher relapse with two inductions.

Hematology-Oncology news Oncology

TP53 Mutations in Acute Myeloid Leukemia: Impact on Outcomes Post-Allogeneic Hematopoietic Cell Transplantation

By MedXY 09/10/2026

TP53 mutations define a high-risk AML subset with inferior survival post-allo-HCT, driven mainly by relapse. Molecular heterogeneity may guide personalized post-transplant strategies.

Hematology-Oncology news Pediatrics

Navigating Therapeutic Approaches in Pediatric Relapsed Acute Myeloid Leukemia: Current Trends and Comparative Outcomes

By MedXY 09/03/2026

This article reviews the variability and comparative effectiveness of re-induction treatments in pediatric relapsed AML, highlighting the role of gemtuzumab ozogamicin and chemotherapy backbones in improving remission rates but not overall survival.

Diabetes & Endocrinology news

Optimizing Antithyroid Drug Duration in Graves’ Disease with Low TRAb: Evidence for Shorter Therapy

By MedXY 07/22/2026

A propensity-weighted analysis suggests that shorter antithyroid drug therapy (<12 months) in Graves' disease patients with low baseline TRAb is broadly comparable to the standard 12-18 months in preventing relapse, supporting individualized treatment duration.

Hematology-Oncology news Pathology & Lab Medicine/Bệnh học

Early High-Resolution Immune Profiles Are Linked to Survival and Relapse After Allogeneic Stem Cell Transplantation

By MedXY 06/02/2026

Early immune profiling after allogeneic stem cell transplant was linked to survival and relapse risk. Stronger innate and adaptive immune recovery predicted better outcomes, while certain activation and checkpoint markers were associated with worse survival.

Hematology-Oncology news

Cellular and Molecular Mechanisms of Relapse After CD19/CD22 Dual-Target CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

By MedXY 06/02/2026

A study of 91 B-ALL patients found that relapse after CD19/CD22 dual-target CAR T-cell therapy is mainly driven by CAR T-cell functional failure and antigen loss, with PAX5 mutations linked to early immune escape.

news Psychiatry

Defining Relapse in Schizophrenia: New International Consensus to Standardize Research and Care

By MedXY 10/30/2025

An international expert consensus offers standardized, operational criteria for defining relapse in schizophrenia to reduce study heterogeneity, improve research comparability, and guide clinical reporting.

Internal Medicine Psychiatry Specialties

Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Older Adults with Schizophrenia: Insights from Hong Kong’s Population-Based Study

By MedXY 10/18/2025

This study compares long-acting injectable to oral antipsychotics in older schizophrenia patients, highlighting benefits in relapse prevention and mortality reduction, with specific considerations for adverse effects.

Clinical Updates news Psychiatry Specialties

Balancing Risks and Benefits: Early Antipsychotic Dose Reduction Versus Maintenance After First-Episode Psychosis Remission

By MedXY 10/01/2025

A randomized clinical trial reveals early dose reduction of antipsychotics after first-episode psychosis remission increases short-term relapse risk and lowers quality of life, but may improve long-term functioning over four years.